Prof. Hou Jian (侯健) — Multiple Myeloma | Renji Hospital, Shanghai Jiao Tong University
For international patients facing a diagnosis of multiple myeloma — a complex, incurable but increasingly manageable blood cancer — the choice of specialist is one of the most consequential decisions they will make. Prof. Hou Jian (侯健) is widely regarded as China's foremost authority on multiple myeloma: a physician who has spent his career building the national framework for myeloma diagnosis and treatment, and who is recognized internationally as a leader in the field. He is known in Chinese hematology circles as “China's Myeloma Man” — a designation that reflects both his clinical expertise and his foundational contributions to the discipline.
Specialty Focus
- Multiple myeloma: newly diagnosed, relapsed, and refractory disease
- Plasma cell disorders: smoldering myeloma, MGUS, AL amyloidosis, Waldenström macroglobulinemia
- CAR-T cell therapy for relapsed/refractory multiple myeloma
- Autologous stem cell transplantation (ASCT)
- Novel agent combinations: proteasome inhibitors, IMiDs, anti-CD38 monoclonal antibodies, BCMA-targeted therapies
- Myeloma-related complications: bone disease, renal impairment, hypercalcemia
Academic & Clinical Titles
- Chief Physician & Professor, Department of Hematology, Renji Hospital, Shanghai Jiao Tong University School of Medicine
- Committee Member, International Myeloma Working Group (IMWG) — the global authority on myeloma diagnosis and treatment standards
- Former Standing Committee Member, Hematology Branch, Chinese Medical Association
- Former Chair, Plasma Cell Disease Study Group, Chinese Society of Hematology
- Principal author and contributor to multiple national and international myeloma treatment guidelines
Why Prof. Hou Jian Stands Apart
Multiple myeloma is a disease where subspecialty depth matters enormously. Treatment decisions — which induction regimen to use, when to transplant, how to sequence novel agents, when to consider CAR-T therapy — require not just knowledge of current guidelines but an understanding of the evolving evidence base and the ability to individualize therapy for each patient's disease biology, comorbidities, and goals.
Prof. Hou Jian brings three distinct advantages to his patients:
1. International Guideline Authority: As a member of the International Myeloma Working Group (IMWG) — the body that sets global standards for myeloma diagnosis, response criteria, and treatment recommendations — Prof. Hou is not merely a follower of international guidelines but a contributor to them. His patients benefit from treatment decisions informed by the most current global evidence, often before it is widely disseminated.
2. National Guideline Leadership: Prof. Hou has been the principal architect of China's national myeloma treatment guidelines, serving as chair of the plasma cell disease study group that defines how myeloma is diagnosed and treated across Chinese institutions. This means his clinical practice reflects both international best practice and deep familiarity with the Chinese healthcare context — including drug availability, reimbursement, and institutional capabilities.
3. Access to Cutting-Edge Therapies: Renji Hospital is one of China's leading centers for CAR-T cell therapy in hematologic malignancies. For relapsed/refractory myeloma patients who have exhausted standard therapies, BCMA-targeted CAR-T therapy — an area where China has made globally significant advances — may be available through Prof. Hou's program. China has approved multiple BCMA CAR-T products and has one of the world's largest clinical experiences with this modality.
Multiple Myeloma: The Treatment Landscape
Multiple myeloma is a cancer of plasma cells in the bone marrow. It is characterized by the production of abnormal immunoglobulin (M-protein), bone destruction, renal impairment, anemia, and immune suppression. While not yet curable with standard therapy, the treatment landscape has been transformed over the past two decades by a succession of highly active novel agents.
Newly Diagnosed Myeloma: Current standard induction therapy for transplant-eligible patients is a triplet or quadruplet regimen combining a proteasome inhibitor (bortezomib or carfilzomib), an immunomodulatory drug (lenalidomide or thalidomide), and dexamethasone — with or without an anti-CD38 monoclonal antibody (daratumumab or isatuximab). Autologous stem cell transplantation (ASCT) remains standard of care for eligible patients, followed by lenalidomide maintenance.
Relapsed/Refractory Myeloma: The treatment of relapsed myeloma has become increasingly complex, with multiple active drug classes available: proteasome inhibitors (bortezomib, carfilzomib, ixazomib), IMiDs (lenalidomide, pomalidomide), anti-CD38 antibodies (daratumumab, isatuximab), anti-SLAMF7 antibody (elotuzumab), XPO1 inhibitor (selinexor), and BCMA-targeted therapies (belantamab mafodotin, teclistamab, ciltacabtagene autoleucel, idecabtagene vicleucel). Sequencing these agents optimally requires the kind of subspecialty expertise that Prof. Hou brings.
BCMA CAR-T Therapy: For patients with triple-class refractory myeloma (refractory to a proteasome inhibitor, an IMiD, and an anti-CD38 antibody), BCMA-targeted CAR-T therapy has produced remarkable response rates — including complete responses in patients with heavily pretreated disease. China has been a global leader in BCMA CAR-T development, with multiple approved products and extensive clinical experience. Prof. Hou's program at Renji Hospital is one of the centers with access to this modality.
Who Should Consider Consulting Prof. Hou Jian
- Newly diagnosed myeloma patients seeking expert second opinion on induction regimen and transplant planning
- Patients with relapsed or refractory myeloma who have progressed on standard therapies
- Triple-class refractory patients being evaluated for CAR-T therapy eligibility
- Patients with high-risk cytogenetics (del17p, t(4;14), t(14;16)) requiring specialized treatment strategies
- Patients with myeloma-related complications (renal failure, severe bone disease, hypercalcemia) requiring expert management
- Patients with related plasma cell disorders: AL amyloidosis, smoldering myeloma, Waldenström macroglobulinemia
- Patients seeking access to clinical trials for novel myeloma therapies
How CMCS Connects You with Prof. Hou Jian
China Medical Concierge Shanghai (CMCS) facilitates access to Prof. Hou Jian for international patients with multiple myeloma and related plasma cell disorders. Our team manages the full coordination process — from remote case review and medical record translation to appointment scheduling, interpretation, and in-hospital support.
To begin, patients or their families are encouraged to share available medical records including bone marrow biopsy and cytogenetics reports, M-protein quantification (SPEP, UPEP, serum free light chains), imaging studies (whole-body low-dose CT or PET-CT), and prior treatment summaries. Prof. Hou's team can conduct an initial remote assessment before any travel to Shanghai is required.
CMCS provides end-to-end support including:
- Medical record translation (English, Arabic, French, and other languages)
- Remote pre-consultation case review
- Appointment coordination with Prof. Hou Jian's clinic at Renji Hospital
- On-site interpretation during consultations and procedures
- CAR-T therapy eligibility assessment and enrollment coordination
- Post-consultation summary and follow-up support
Contact CMCS to Connect with Prof. Hou Jian
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
CMCS – China Medical Concierge Shanghai connects international patients with Shanghai's leading specialists. We are a health management company, not a hospital. All clinical decisions are made by the treating physician.
0 comentarios